199 related articles for article (PubMed ID: 26771808)
1. Infectious complications in children with acute myeloid leukemia: decreased mortality in multicenter trial AML-BFM 2004.
Bochennek K; Hassler A; Perner C; Gilfert J; Schöning S; Klingebiel T; Reinhardt D; Creutzig U; Lehrnbecher T
Blood Cancer J; 2016 Jan; 6(1):e382. PubMed ID: 26771808
[TBL] [Abstract][Full Text] [Related]
2. Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004.
Hassler A; Bochennek K; Gilfert J; Perner C; Schöning S; Creutzig U; Reinhardt D; Lehrnbecher T
Pediatr Blood Cancer; 2016 Jun; 63(6):1070-4. PubMed ID: 26814618
[TBL] [Abstract][Full Text] [Related]
3. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
Creutzig U; Zimmermann M; Reinhardt D; Dworzak M; Stary J; Lehrnbecher T
J Clin Oncol; 2004 Nov; 22(21):4384-93. PubMed ID: 15514380
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of causes of death during intensive chemotherapy according to treatment protocol AML-BFM 93].
Creutzig U; Zimmermann M; Reinhardt D; Lehrnbecher T
Klin Padiatr; 2003; 215(3):151-8. PubMed ID: 12778355
[TBL] [Abstract][Full Text] [Related]
5. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93.
Lehrnbecher T; Varwig D; Kaiser J; Reinhardt D; Klingebiel T; Creutzig U
Leukemia; 2004 Jan; 18(1):72-7. PubMed ID: 14586478
[TBL] [Abstract][Full Text] [Related]
6. Low incidence of sepsis due to viridans streptococci in a ten-year retrospective study of pediatric acute myeloid leukemia.
Brunet AS; Ploton C; Galambrun C; Pondarré C; Pages MP; Bleyzac N; Freydière AM; Barbé G; Bertrand Y
Pediatr Blood Cancer; 2006 Nov; 47(6):765-72. PubMed ID: 16333838
[TBL] [Abstract][Full Text] [Related]
7. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.
Creutzig U; Zimmermann M; Ritter J; Reinhardt D; Hermann J; Henze G; Jürgens H; Kabisch H; Reiter A; Riehm H; Gadner H; Schellong G
Leukemia; 2005 Dec; 19(12):2030-42. PubMed ID: 16304570
[TBL] [Abstract][Full Text] [Related]
8. Association between corticosteroids and infection, sepsis, and infectious death in pediatric acute myeloid leukemia (AML): results from the Canadian infections in AML research group.
Dix D; Cellot S; Price V; Gillmeister B; Ethier MC; Johnston DL; Lewis V; Michon B; Mitchell D; Stobart K; Yanofsky R; Portwine C; Silva M; Bowes L; Zelcer S; Brossard J; Traubici J; Allen U; Beyene J; Sung L
Clin Infect Dis; 2012 Dec; 55(12):1608-14. PubMed ID: 22955431
[TBL] [Abstract][Full Text] [Related]
9. Mortality in overweight and underweight children with acute myeloid leukemia.
Lange BJ; Gerbing RB; Feusner J; Skolnik J; Sacks N; Smith FO; Alonzo TA
JAMA; 2005 Jan; 293(2):203-11. PubMed ID: 15644547
[TBL] [Abstract][Full Text] [Related]
10. Predictors and outcomes of viridans group streptococcal infections in pediatric acute myeloid leukemia: from the Canadian infections in AML research group.
Lewis V; Yanofsky R; Mitchell D; Dix D; Ethier MC; Gillmeister B; Johnston D; Michon B; Stobart K; Portwine C; Silva M; Cellot S; Price V; Bowes L; Zelcer S; Brossard J; Beyene J; Sung L
Pediatr Infect Dis J; 2014 Feb; 33(2):126-9. PubMed ID: 24064558
[TBL] [Abstract][Full Text] [Related]
11. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's cancer group study CCG-2891.
Gamis AS; Howells WB; DeSwarte-Wallace J; Feusner JH; Buckley JD; Woods WG
J Clin Oncol; 2000 May; 18(9):1845-55. PubMed ID: 10784625
[TBL] [Abstract][Full Text] [Related]
12. Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG).
Lech-Maranda E; Seweryn M; Giebel S; Holowiecki J; Piatkowska-Jakubas B; Wegrzyn J; Skotnicki A; Kielbinski M; Kuliczkowski K; Paluszewska M; Jedrzejczak WW; Dutka M; Hellmann A; Flont M; Zdziarska B; Palynyczko G; Konopka L; Szpila T; Gawronski K; Sulek K; Sokolowski J; Kloczko J; Warzocha K; Robak T
Int J Infect Dis; 2010 Feb; 14(2):e132-40. PubMed ID: 19581118
[TBL] [Abstract][Full Text] [Related]
13. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
[TBL] [Abstract][Full Text] [Related]
14. Impact of registration on clinical trials on infection risk in pediatric acute myeloid leukemia.
Dix D; Aplenc R; Bowes L; Cellot S; Ethier MC; Feusner J; Gillmeister B; Johnston DL; Lewis V; Michon B; Mitchell D; Portwine C; Price V; Silva M; Stobart K; Yanofsky R; Zelcer S; Beyene J; Sung L
Int J Cancer; 2016 Apr; 138(7):1785-91. PubMed ID: 26515793
[TBL] [Abstract][Full Text] [Related]
15. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
Creutzig U; Reinhardt D; Diekamp S; Dworzak M; Stary J; Zimmermann M
Leukemia; 2005 Aug; 19(8):1355-60. PubMed ID: 15920490
[TBL] [Abstract][Full Text] [Related]
16. Treatment results of three consecutive German childhood AML trials: BFM-78, -83, and -87. AML-BFM-Group.
Ritter J; Creutzig U; Schellong G
Leukemia; 1992; 6 Suppl 2():59-62. PubMed ID: 1578943
[TBL] [Abstract][Full Text] [Related]
17. Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen.
Girmenia C; Lo Coco F; Breccia M; Latagliata R; Spadea A; D'Andrea M; Gentile G; Micozzi A; Alimena G; Martino P; Mandelli F
Leukemia; 2003 May; 17(5):925-30. PubMed ID: 12750707
[TBL] [Abstract][Full Text] [Related]
18. High frequency of streptococcal bacteraemia during childhood AML therapy irrespective of dose of cytarabine.
Johannsen KH; Handrup MM; Lausen B; Schrøder H; Hasle H
Pediatr Blood Cancer; 2013 Jul; 60(7):1154-60. PubMed ID: 23281248
[TBL] [Abstract][Full Text] [Related]
19. Clinical and microbiologic outcomes of quinolone prophylaxis in children with acute myeloid leukemia.
Felsenstein S; Orgel E; Rushing T; Fu C; Hoffman JA
Pediatr Infect Dis J; 2015 Apr; 34(4):e78-84. PubMed ID: 25764103
[TBL] [Abstract][Full Text] [Related]
20. Lack of Effectiveness of Neutropenic Diet and Social Restrictions as Anti-Infective Measures in Children With Acute Myeloid Leukemia: An Analysis of the AML-BFM 2004 Trial.
Tramsen L; Salzmann-Manrique E; Bochennek K; Klingebiel T; Reinhardt D; Creutzig U; Sung L; Lehrnbecher T
J Clin Oncol; 2016 Aug; 34(23):2776-83. PubMed ID: 27269945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
